Juvenal Tobin W's Form 4 filing
Castle Biosciences IncCSTL · filed Aug 6, 2026
- Accession no.
- 0001628280-26-054338
- Filed
- Aug 6, 2026, 4:14 PM ET
- Trade date
- Nov 24, 2025
- Filing delay
- 255 daysLate
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $49.9K. It was filed 255 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Juvenal Tobin WCIK 0001856542 | Officer (Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 24, 2025 | Common Stock | SSaleDisposed | −1,301 | $38.39 | −$49,945.39 | 77,694 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.